China's NMPA approves initiation of InnoCare's trial of B7-H3 targeted ADC
This marks a step forward in the development of targeted therapies for solid tumours, including oesophageal, nasopharyngeal, lung, prostate cancers, and head and neck squamous cell carcinomas, among others.
The ADC is designed to deliver a potent payload through a protease-cleavable linker. This targeting mechanism is expected to decrease off-target effects and improve treatment outcomes for patients with solid tumours.
According to the company, there are currently no B7-H3-targeted therapies that have received marketing approval.
This type I transmembrane protein is expressed highly in various solid tumours and is observed as a potential anti-tumour target.
InnoCare Pharma chairwoman, CEO and co-founder Dr Jasmine Cui said: "ICP-B794 is developed from the company's proprietary ADC platform. The platform is designed to deliver ADCs with strong tumour-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients and improving their clinical outcomes.
'As the platform continues to evolve, the company is poised to expand its portfolio with multiple differentiated ADC candidates, further advancing precision medicine in oncology."
InnoCare is focused on developing a drug portfolio targeting a wide range of solid tumour indications.
The company's research and development (R&D) team discovers and develops platforms to address solid tumours. Their approach includes leveraging technologies to detect and progress potential drug candidates that could provide clinical advantages.
Its ADC technology platform is complemented by precision medicine candidates like the tropomyosin receptor kinase (TRK) inhibitor zurletrectinib (ICP-723).
In February 2025, the NMPA approved a Phase III trial of InnoCare Pharma's ICP-248 (Mesutoclax) with orelabrutinib as a first-line therapy for chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL).
"China's NMPA approves initiation of InnoCare's trial of B7-H3 targeted ADC" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Is a Chinese chain's blood orange cold brew the future of coffee in America?
Chinese chain Luckin Coffee opened its first two U.S. locations this week, betting that mobile-only ordering and creative flavors can lure customers away from Starbucks. Both new Luckin stores are based in Manhattan, and at the midtown location on Wednesday, Sam Liu took a sip of her jasmine cold brew. 'I've never tried anything like it,' she said. Liu said she'd hoped for more seating — the small shop has only three tables — and was initially confused by Luckin's in-app ordering system, which means customers can't order directly from a barista. 'I thought I just order at the counter, but I realized everyone was standing around looking at their phone,' Liu said. Luckin is China's largest coffee chain, with more than twice as many locations as Starbucks there. Its two New York City stores are its first foray outside Asia, where it has over 24,000 locations across the region. By comparison, there are over 17,000 Starbucks in the United States. Its CEO, Guo Jinyi, called the U.S. 'a strategically important market' for the company's expansion in a press release heralding the two new locations Wednesday. 'We are excited to introduce a diverse and unique coffee experience to American consumers.' The company, which didn't respond to a request for comment, has touted its ambitions to expand globally but hasn't publicly detailed its next moves in the U.S. or other markets. The chain has gained success overseas through creative drinks like alcohol-infused coffees and fruit lattes, along with its smartphone-centric ordering model. The app-based approach makes it easier to track inventory, send personalized appeals to consumers and serve drinks quickly, said John Zolidis, an analyst who tracks Luckin and Starbucks at the brokerage firm he founded, Quo Vadis Capital. 'Luckin was able to develop an incredible muscle with regard to product innovation, and they have been very creative in China,' he said. Zolidis said how Luckin fares on Starbucks' home turf will depend on its ability to differentiate its menu from other major U.S. coffee chains and smaller, independent cafes. Its American lineup already includes distinctive drinks like blood orange cold brew and coconut lattes. 'These orange drinks, or one of their most successful, a coconut cloud latte — that's how you get trial [customers] from the U.S.,' Zolidis said. Luckin faced financial troubles during the pandemic. It was delisted from Nasdaq in 2020 after its stock plunged following an internal investigation that found an executive had falsified revenue reports. The company filed for bankruptcy in the U.S. the following year but emerged from proceedings in 2022 and its sales have soared since, reaching $4.7 billion worldwide in fiscal year 2024, a 38.4% increase from 2023. Starbucks, by contrast, is struggling in both the U.S. and China. Its same-store sales in the U.S. declined 2% and its sales in China 8% in fiscal year 2024, and it reported in April that its quarterly profit was half of what it pulled in for the same period last year. The Seattle-based chain is reportedly looking to partially sell its business in China while revamping its U.S. strategy to focus on customer experience and human connection, in contrast with Luckin's model. 'We veered away from, I think, owning the idea of the 'third place,' the coffeehouse experience, making sure that the customer was front and center,' Starbucks CEO Brian Niccol told NBC News in June. A Starbucks spokesperson declined to comment. Zolidis said that whereas Starbucks aims in both the U.S. and China to appeal to customers looking for higher-end coffee served in an inviting setting, Luckin has successfully positioned itself as the 'everyman's coffee' in China, with low prices and small, grab-and-go storefronts. After taking the train in from Hoboken, New Jersey, to check out the new one in midtown, Samantha Coy said the trip was worth it. She had enjoyed Luckin in China previously and was eager to order one of its fruit drinks. 'I'm surprised Starbucks hasn't tried to bring that over to the U.S.,' Coy said. 'I hope they stay open.' Zolidis said he thinks Luckin is well-positioned to gain a foothold in America. 'They've been able to operate and grow incredibly quickly in the Chinese market, much faster than I would have thought possible, and they've been able to sustain it and develop a strong financial model so they can fund their expansion in the U.S.,' Zolidis said. 'They wouldn't be coming here to try it if they didn't think they had a shot of owning part of the market.' This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
New Models, Robotaxi, and AI: Why Tesla's (TSLA) Still a Buy After Delivery Dip
Tesla, Inc. (NASDAQ:) is one of the . On July 2, Canaccord Genuity analyst George Gianarikas reiterated a Buy rating on the stock with a $303.00 price target. The rating affirmation follows Tesla's second-quarter delivery results, which exceeded Canaccord's recently lowered estimates by approximately 24,000 units. In particular, strong performance was witnessed in China, Norway, France, Spain, and Turkey, which led to the better-than-feared results. Regardless of this positivity, Tesla suffered its largest decline in year-over-year deliveries, falling 14% compared to Q2 2024. This is, the firm believes, largely due to Musk's political endeavors. Nevertheless, catalysts such as new models, traction from the revamped Model Y, and the expectations surrounding the Robotaxi announcement are likely to work for Tesla for the remainder of the year. Energy storage deployments also witnessed a slowdown, with the firm concerned about the development of energy structure for artificial intelligence. It stated that 'EVs drive the P&L, now and for the foreseeable future' and also stressed the need to see growth in Tesla's core business. Tesla, Inc. (NASDAQ:TSLA) is an automotive and clean energy company that leverages advanced artificial intelligence in its autonomous driving technology and robotics initiatives. While we acknowledge the potential of TSLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 AI Stocks in the Spotlight and . Disclosure: None.
Yahoo
2 hours ago
- Yahoo
Apple (AAPL) Stock Upgraded to ‘Hold' by Jefferies — But Analysts Still Cautious on AI
Apple Inc. (NASDAQ:) is one of the . On July 2, Jefferies upgraded the stock to 'Hold' from underperform and raised the price target to roughly $188 per share from $171. Analyst Edison Lee highlighted Apple's 15% annual growth in sales volume in April and May as a catalyst behind the upgrade. Lee also estimated that iPhone sales grew 19% year over year during the June 18 Chinese shopping holiday. 'This is a strong sign that AAPL is determined to defend market share in China, and Chinese consumers are still willing to buy iPhone at lower prices. We believe 40m units is likely the minimum AAPL is looking to maintain in China,' the analyst wrote. 'Given the special situation in the last 3 months, we see potential upside surprise for AAPL's 3QFY25 results.' A good June quarter 'could keep the stock stable near term.' However, he further cautioned that strong June quarter sales could imply slow demand in the September quarter. 'Jun Q results could be a positive surprise, but Sep Q guidance would likely still be subdued.' 'We believe the sales could be at risk since there remains a lack of new features, and AI is not yet a game changer. We are worried about the attractiveness of 17 Slim, since 1) it has only one camera, 2) its battery capacity is likely at only 2,800 mAh, and 3) a higher selling price than 16 Plus.' Apple may also be facing long-term risks, such as a downside in revenue from the App Store, the firm noted. Apple is a technology company known for its consumer electronics, particularly the iPhones and MacBooks. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 AI Stocks in the Spotlight and . Disclosure: None.
